HER2 - a discussion of testing approaches in the USA

被引:34
作者
Thor, A [1 ]
机构
[1] Evanston NW Healthcare, Dept Pathol, Evanston, IL 60201 USA
[2] Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA
关键词
doxorubicin; HER2; Herceptin; prediction; prognosis; tamoxifen; trastuzumab;
D O I
10.1023/A:1011120309910
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
HER2 (neu, erbB-2), a receptor related to the human epidermal growth factor receptor, has now become more important as a predictive marker of treatment response. While the value and direction of the treatment/HER2 interaction may vary, depending on the agents, dose, or schedule of drug administration, there is little disagreement that HER2 testing is an important part of breast cancer evaluation. In 1998, trastuzumab (Herceptin) was approved for the treatment of HER2-positive metastatic breast cancer patients by the Food and Drug Administration of the USA. Patients with abnormal HER2 in their breast cancer cells (generally 2 or 3+ with the HercepTest, overexpression by other immunohistochemical assays or amplification by fluorescence in situ hybridization [FISH] assay) have demonstrated the greatest response to trastuzumab treatment. It is unclear which test (method, reagent, cut-off points, etc.) is best to use to evaluate HER2 for this purpose because parallel testing of the same cancers from patients who received trastuzumab has only recently been initiated and the data are limited. It is widely believed that breast cancers without HER2 alterations will not be responsive to trastuzumab, although a clinical trial to test this specific hypothesis has not been initiated. There are also concerns that clonal heterogeneity for HER2 within a tumor, or between primary and metastatic cancer foci, may affect treatment response; yet we do not currently evaluate these parameters. Consensus regarding the best methods, reagents, or cut-off points to define HER2 status for determining trastuzumab responsivity has not yet been reached. HER2 testing for other prognostic or predictive purposes, e.g. to determine whether patients are likely to respond to other agents, such as dose-intensive doxorubicin, may be less. Data from the Cancer and Leukemia Group B trial 8541 (companion 8869) suggest that, with proper controls in high-volume laboratories, many of the available methods produce comparable results.
引用
收藏
页码:101 / 107
页数:7
相关论文
共 22 条
[1]   ESTROGEN-DEPENDENT, TAMOXIFEN-RESISTANT TUMORIGENIC GROWTH OF MCF-7 CELLS TRANSFECTED WITH HER2/NEU [J].
BENZ, CC ;
SCOTT, GK ;
SARUP, JC ;
JOHNSON, RM ;
TRIPATHY, D ;
CORONADO, E ;
SHEPARD, HM ;
OSBORNE, CK .
BREAST CANCER RESEARCH AND TREATMENT, 1992, 24 (02) :85-95
[2]  
BORG A, 1990, CANCER RES, V50, P4332
[3]   c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases [J].
Carlomagno, C ;
Perrone, F ;
Gallo, C ;
DeLaurentiis, M ;
Lauria, R ;
Morabito, A ;
Pettinato, G ;
Panico, L ;
DAntonio, A ;
Bianco, AR ;
DePlacido, S .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (10) :2702-2708
[4]  
COLOMER R, 1992, P AACR, V33
[5]   HER2 as a prognostic and predictive marker for breast cancer [J].
Cooke, T ;
Reeves, J ;
Lanigan, A ;
Stanton, P .
ANNALS OF ONCOLOGY, 2001, 12 :23-28
[6]  
DRESSLER LG, 2000, ANN ONCOL
[7]  
Elledge RM, 1998, CLIN CANCER RES, V4, P7
[8]  
Fitzgibbons PL, 2000, ARCH PATHOL LAB MED, V124, P966
[9]   ELEVATED SERUM C-ERBB-2 ANTIGEN LEVELS AND DECREASED RESPONSE TO HORMONE-THERAPY OF BREAST-CANCER [J].
LEITZEL, K ;
TERAMOTO, Y ;
KONRAD, K ;
CHINCHILLI, VM ;
VOLAS, G ;
GROSSBERG, H ;
HARVEY, H ;
DEMERS, L ;
LIPTON, A .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (05) :1129-1135
[10]   HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer [J].
Ménard, S ;
Casalini, P ;
Campiglio, M ;
Pupa, S ;
Agresti, R ;
Tagliabue, E .
ANNALS OF ONCOLOGY, 2001, 12 :15-19